Pharmacists News

• NKF 2025 Sparsentan Provides Better Proteinuria Reduction in FSGS A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.
  Medscape Medical News, April 11, 2025
• NKF 2025 Chlorthalidone Increases Kidney Stone Recurrence A secondary analysis of the DCP shows that, compared with hydrochlorothiazide, chlorthalidone significantly increases the risk of kidney stones — but only among those with prior stones.
  Medscape Medical News, April 11, 2025
• Worldwide, Doctors Report Harassment — and Inaction Doctors report mental health effects, isolation, and even quitting their jobs — yet perpetrators rarely face consequences.
  Medscape Medical News, April 11, 2025
• Alert NICE Recommends Capivasertib for Advanced Breast Cancer The targeted drug capivasertib will be available immediately for some patients in England with advanced breast cancer.
  Medscape News UK, April 11, 2025
• AAN 2025 Novel Agent for AD Agitation Continues to Show Promise Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.
  Medscape Medical News, April 11, 2025
• Australia Braces for Major Influenza, RSV, Pertussis Season Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and pertussis surge earlier than expected.
  Medscape Medical News, April 11, 2025
• 4 Things to Know About New Medicare Advantage Rules Prior authorization leeway will be trimmed while health plans get more money under new federal rules for Medicare Advantage plans.
  Medscape Medical News, April 11, 2025
• ACP-IM 2025 Eye-Opening Updates in Insomnia and OSA Expert shares treatment approaches for insomnia and alternatives for patients With PAP-intolerance.
  Medscape Medical News, April 11, 2025
• Canadian Pediatricians Ill Prepared to Treat Drug Overdoses Illicit drug toxicity is an ‘escalating public health emergency’ in Canada that affects adolescents as well as adults.
  Medscape Medical News, April 11, 2025
• Alert FDA Clears Dexcom G7 CGM for 15-Day Wear The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.
  Medscape Medical News, April 10, 2025
• Alert NICE Backs Oral Drug for Advanced Bladder Cancer NICE has approved the oral drug erdafitinib for adults with advanced urothelial cancer and FGFR3 alterations, offering new hope and home-based treatment.
  Medscape News UK, April 10, 2025
• Can Shorter Antibiotic Treatment Benefit Kids With UTIs? Individualised antibiotic treatment increases the risk for recurrence but reduces antibiotic use and the number of adverse event days in children with febrile UTIs, a Danish trial reveals.
  Medscape News UK, April 10, 2025
• DLBCL: Novel Drug Combo Boosts Survival in Older Adults Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.
  Medscape Medical News, April 10, 2025
• Why Listening to Patients Matters in Rare Disease Research Gene therapy isn’t one-size-fits-all: Patient associations are shaping trials, asking hard questions, and demanding realistic timelines for treatment delivery.
  Medscape Medical News, April 10, 2025
• Methylene Blue: Miracle Cure or Dangerous Trend? As influencers tout methylene blue as a cognitive enhancer and anti-aging solution, experts caution about its serious risks and lack of evidence.
  Medscape Medical News, April 10, 2025
• AAN 2025 AI-Powered Wearable Calms Essential Tremor The Felix NeuroAI wristband delivers tailored and dynamic electrical stimulation to the ulnar, median, and radial nerves throughout the day to relieve essential tremor.
  Medscape Medical News, April 10, 2025
• The Era of Compounded GLP-1 Drugs Is Over. What Now? Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.
  Medscape Medical News, April 10, 2025
• AAN 2025 Inebilizumab Effective Up to 52 Weeks in Myasthenia Gravis Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.
  Medscape Medical News, April 10, 2025
• ACC 2025 Rivaroxaban Comparable to Warfarin for LV Thrombus Post-MI The direct oral anticoagulant is an effective alternative to warfarin that offers predictable dosing without the need for routine monitoring in patients with STEMI, the RIVAWAR trial shows.
  Medscape Medical News, April 10, 2025
• Cardiac Dysfunction Surfaces Early With Cancer Treatment Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.
  Medscape Medical News, April 10, 2025